This document provides an overview of S.B. Group Ltd., an Israeli company that develops innovative solutions to enhance quality of life for seniors. The company specializes in products that help with daily living tasks like putting on socks. The Sockee and Stockeez products assist those with mobility issues in independently putting on and taking off socks and medical compression stockings. The company is seeking funding to expand its product line and sales in markets like the US, EU, Israel, and Australia. It has patents, manufacturing capabilities, and distribution agreements to facilitate growth goals of increasing monthly sales over the next year.

1. COMPANY OVERVIEW
2017PARNASA 61 – Biomedical Fund
S.B GROUPJULY 2017

2. COMPANY OVERVIEW
 Our goal is to enhance quality of life and
facilitate independent later lifestyle
 We specialize in the development,
production and marketing of innovative
solutions for the golden age
 Established and found by Tal Shahar and
Reuven Boaron on Dec 2012
 S.B. Group Ltd. is an Israeli company,
registered in May 2015; Company ID #
515251106
2017PARNASA 61 – Biomedical Fund

3. Putting socks on and taking them off…
A task, considered easy by most, may become a major obstacle to people with mobility issues.
The Sockee sock aid is a unique device, developed to assist anyone with difficulty bending
down to put on and take off socks in an independent and safe method.
http://www.thesockee.com
http://thestockeez.com (under construction)
INTRODUCING
2017PARNASA 61 – Biomedical Fund

4. PRODUCT
LINE
2017
• Designed for medical compression stockings
• Medical condition use
• Para medical device (CE class 1 medical device)
• End user price up to $70
• Covered by health care insurance (in some countries)
• Designed for regular socks
• Designed for daily use for all users
• Home care / consumer product
• End user price up to $40
PARNASA 61 – Biomedical Fund
Two products for two segments
SOCKEE - consumer product “daily living aids”
STOCKEEZ - para medical device

5. COMPANY ASSETS
2017PARNASA 61 – Biomedical Fund
• IP
 US9119494B2 – granted
http://www.google.com/patents/US9119494
 P-14823 USP – provisional
• Operation
 Molds and tooling for mass production located in China
 Active production line in China
 Full Production files – BOM, 3D drawings & QA procedures
 Logistics chain – Storage and fulfillment center in US and Israel
 Customer support Rep.
• Marketing and Sells
 Online B2C website www.thesockee.com – US market
 Signed and running distribution agreements in Germany & Austria
/ Italy & Spain / France / Israel / Australia & NZ

6. TARGET MARKET-STOCKEEZ
(STOCKEEZ)
2017PARNASA 61 – Biomedical Fund
http://www.reuters.com/article/research-and-marketsidUSnBw285576a+100+BSW20130828
Medical condition: Tired aching legs, Edema, Chronic venous
insufficiency, Varicose veins, Spider veins (mild varicosities) , Deep
vein thrombosis, Lymphedema, Phlebitis, Economy class syndrome
(ECS), Lipodermatosclerosis, Pregnancy, Prophylaxis.
The global compression therapy market was valued at $2.4 billion in
2012 and is forecast to reach $3.4 billion by 2019 at a Compound
Annual Growth Rate (CAGR) of 5%. It will be driven primarily by the
increasingly large population that is both elderly and diabetic and
leading to a high incidence of venous diseases.
Average compression stocking pair $80 = 30M pairs of socks
sold each year (2012)

7. TARGET MARKET-STOCKEEZ
(SOCKEE)
2017PARNASA 61 – Biomedical Fund

8. TARGET MARKET-SOCKEE
2017PARNASA 61 – Biomedical Fund
Elderly
In 2010, 40 million people age 65 and over lived in the United States,
accounting for 13 percent of the total population.
The older population grew from 3 million in 1900 to 40 million in 2010. The
oldest-old population (those age 85 and over) grew from just over 100,000 in
1900 to 5.5 million in 2010. The older population is growing rapidly, and the
aging of the “Baby Boomers” born between 1946 and 1964 (and who began
turning age 65 in 2011), are accelerating this growth.
About 5% of the western world dealing with common mobility problems.

9. TARGET MARKET
2017PARNASA 61 – Biomedical Fund
Obesity
Since the early 1960s, the prevalence of obesity among adults more than
doubled, increasing from 13.4 to 35.7 percent in U.S. adults age 20 and
older.
Arthritis and other Joint Diseases
Between 200,000 and 300,000 hip replacement operations are performed in
the United States each year, most of them in patients over the age of 60.
Pregnancy
Each year in the United States, there are approximately 6 million
pregnancies. This means that at any one time, about 4% of women in the
U.S. are pregnant.
TARGET MARKET-SOCKEE

10. MARKETING & SALES
CHANNELS
2017PARNASA 61 – Biomedical Fund
SOCKEE
• Home care/ consumer product
 On-line B2C
 Agent & Field Rep’s (USA)
 Retailers / wholesalers
 DRTV
STOCKEEZ
• Para medical device
 Professional distribution channels
(medical suppliers)
 Professional POS (mainly orthopedic
shops)
 Agent & Field Rep’s (USA)
 Doctors and therapists
 On line B2C

11. 2017 & 2018 GOALS
2017PARNASA 61 – Biomedical Fund
• H2 2017-
 Delivery first order to EU & Israel partners - total of 6000 units
 Open the US market / Agent & field rep’s – 2000-6000 units
 Attending RehaCare 2017 trade show – expand the business to UK and East Europe
• H1 2018-
 Delivery of first order to UK & East Europe partner
 EU & Israel - Average monthly sales of 4000 units total
 USA – average monthly sales of 6000 units total
 Launching new device for donning compression stocking while laying in bed
• H2 2018-
 EU - Average monthly sales of 6000 units total
 USA – average monthly sales of 8000 units total
 Launching electric power version for Stockeez

12. OPPORTUNITY
The market is here, endless,
growing, well known and
reachable (mainly the “baby
boomer” generation).
In the market of the shelf –
stable production line and
logistic chain.
Huge potential in the medical
stockings segment.
Patented, unique, proven
solution for normal and
compression stockings.
2017PARNASA 61 – Biomedical Fund
Versatile solution both for
medical stockings and normal
socks.
Clear view on high volume
sales in US, EU, UK &
Israel.
Experienced highly motivated
and professional team.

13. PARNASA 61- Biomedical Fund
An Israeli company managed by Parnasa Nihul Basad Ltd, seeking to raise $1.715 million
in equity capitalization.
The Company’s investment objective is to generate superior long-term capital
appreciation through private equity investments in early-stage private companies
primarily based in the United States and Israel.
The Investment Manager is controlled by Eliezer Gross who holds a controlling interest of
management shares of the Company. The Investment Manager will be responsible for
the Company’s investment strategy and the management of the Company. He will
perform all day-to-day investment and asset management functions for the Company,
subject to the supervision and direction of the Company’s Board of Directors.
The Company has been formed to make seed and early-stage investments in the common
stock and preferred stock of start-up biomedical ventures located in Israel.
2017PARNASA 61 – Biomedical Fund

14. INVESTMENT STRATEGY
2017
 The Company intends to invest substantially all of the proceeds of the sale of Shares
offered in the existing portfolio.
 In addition, the Company may invest (or reinvest proceeds of exited investments) in one or
more other start-up technology ventures from time to time subject to the availability of
resources.
 The Company intends to have multiple closings so that any money that comes in could
immediately be used by the Company even if it is below the total amount of capital
sought to be raised pursuant to the official offering.
PARNASA 61 – Biomedical Fund

15. The Company’ s existence is perpetual and therefore
dissolution and/or distribution of all or part of the
Company’s assets are not expected at any
time in the future.
2017
6000 shares = $10,625.
Fund will bear all costs and expenses.
The Company is being treated as a corporation under
the Israeli tax laws.
December 31
25%
FUND
LIFE(TERM):
MINIMUM
PURCHASE:
OFFERING &
ORGANISATION
EXPENSES:
TAXATION:
FUND STRUCTURE
FISCAL YEAR
END:
CARRIED
INTEREST:
PARNASA 61 – Biomedical Fund

16. MANAGEMENT TEAM
With over 30 years of experience launching business
ventures in Israel, the United States, and Europe.
He was a founding partner of the American GBM Group,
and of the largest retail chains in Israel. Active in dozens
of startup initiatives and companies worldwide, he knows
the U.S market inside and out and has been influential in
developing many new products.
His keen business acumen has led him through the doors
of dozens of leading companies – primarily from the
Fortune 100 including: Johnson & Johnson Corporation,
CBS Studios, Goodyear Tires, et al.ELIEZER GROSS
FOUNDER AND CHAIRMAN
2017PARNASA 61 – Biomedical Fund

17. MANAGEMENT TEAM
2017PARNASA 61 – Biomedical Fund
Cobi Bitton
CEO, Besadno Group
Mr. Bitton is an entrepreneur, organizational consultant, and
expert in business development and the study of entrepreneurial
business models. He holds a Bachelor's degree in Industrial and
Management, an MBA and is highly knowledgeable about
conventional industrial production, environmental issues, and
safety and security products.
He was one of the entrepreneurs and founders of the SEC (Safe
Evacuation Coalition) - an advocacy group formed by companies,
and dedicated to promoting advanced emergency means of
egress solutions in the global market.
He has been counseling businesses, entrepreneurs, startups and
corporations for the past 25 years, empowering clients in the
American, Eastern and Central European, Latin, Russian, and
East Asian markets, among other locations. Cobi serves as the
CEO of Israel - Greece Chamber of Commerce, voluntarily.

18. MANAGEMENT TEAM
2017PARNASA 61 – Biomedical Fund
Gabby Hasson
CEO, Bseed Investments
Gabby is the CEO and Co-Founder of Bseed Investments,
with over 25 years of proven experience in the Investment,
IT and cutting-edge technology space in navigating and
uncovering opportunities for excellent growth and
profitability.
Previously, Gabby held management, Investment, and
business development positions, at CB Alliance (VC), IBM,
and HP, as well as Mashik Consulting and CTI. He
specialized in uncovering and enhancing solutions for
Mobile Telecom, Banking, and Online Marketing. Gabby
gained vast experience with IBM's Global Technology Unit
(GTU), that focused on startups and innovations.

19. MANAGEMENT TEAM
2017PARNASA 61 – Biomedical Fund
Mr. Eliashiv (LLB) is the Head of Development in the
Besadno Group. Oded has vast experience in the
Israeli startup industry, having led numerous ventures
in leading companies including Excellence Capital
Group (Singapore), Excellence AgriTech Solutions
(Cambodia), Slyde, ElectroPep, Beyond Interactive and
Epos Technologies.
Using his extensive experience in the startup
ecosystem, Oded is now advising early-stage startups
and providing them with the mentoring and fundraising
assistance.Oded Eliashiv
Head of Development,
Besadno Group